When historians eventually document the modern psychedelic renaissance in Australia, they will likely focus on a handful of landmark moments. The launch of the country’s first psychedelic clinical trials. The emergence of dedicated research organisations. The formation of advocacy groups that brought psychedelic medicine into the public conversation. And perhaps most significantly, the Therapeutic Goods […]
Already subscribed? Log in
US-listed BioAdaptives, Inc. (OTCID: BDPT) has signed a definitive agreement to acquire Xycota Biosciences LLC, a privately held biotechnology company developing experimental psychedelic medicines for psychiatric and neurological...
Canadian biotechnology company PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) has signed an agreement with Corealis Pharma Inc., a contract development and manufacturing organisation based in Laval,...
New preclinical findings suggest EB-003 can alter brain activity without producing some of the adverse neurological effects observed with DMT in mice. Enveric Biosciences (NASDAQ: ENVB) has reported...
Now part of Rhelion Life Sciences, Canadian pharmaceutical developer Filament Health is supplying naturally derived psilocybin for clinical research worldwide, including a new study investigating social anxiety disorder...
Psychedelics.media delivers trusted news, intelligence, and insights for the global psychedelic medicine industry.
